Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Eliquis meets in Phase III for acute VTE

Bristol-Myers Squibb Co. (NYSE:BMY) and partner Pfizer Inc. (NYSE:PFE) said twice-daily oral Eliquis apixaban for six months met the primary endpoint of non-inferiority to conventional therapy consisting of

Read the full 288 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE